Diligence memo · auto-generated · as of July 2, 2026
Curebase, Inc.
Curebase, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Curebase, Inc. operates in AI / ML, based in Walnut, CA, USA; Remote. Modern, AI-powered clinical trial software platform.
Sub-sector tags: Healthcare, ai/ml.
Capital & rounds (filed)filed
Curebase, Inc. has raised $19M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2021-04-27.
Most recent recorded round closed around 2021-04-27.
Valuation (modeled)modeled
Provath models Curebase, Inc. at approximately $469M (range $40M–$1.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.96× the median modeled value of Series B AI / ML companies in 2019–2021 (22 peers) — value vs value, same stage and era. Within the normal band (96% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 30 months.
Last raise 5.2 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 6.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 92% of AI / ML peers (2067 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Nile AI, Inc., Outlier AI, Inc., ClosedLoop.ai Inc., Airbyte, Inc., Common Intelligence, LLC.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.